文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
I. Thalmann
发表
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.